Trials 12
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT01031537 | Sep 2009 → Dec 2016 | surface antigen, glycoprotein 75, tick-borne encephalitis | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 2 | NCT00890422 | Mar 2007 → Nov 2009 | tick-borne encephalitis | Elisabethinen Hospital | Unknown | No outcome recorded |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT00840801 | Feb 2009 → May 2010 | tick-borne encephalitis | Pfizer | Completed | Met primary |
| Phase 3 | NCT00460486 | Sep 2006 → Nov 2007 | tick-borne encephalitis | Pfizer | Completed | No outcome recorded |
| Phase 48 trials | ||||||
| Phase 4 | NCT01582698 | Apr 2012 → Jun 2015 | tick-borne encephalitis | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00894686 | Apr 2009 → May 2017 | tick-borne encephalitis | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00804219 | Dec 2008 → Nov 2010 | tick-borne encephalitis | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT00503529 | Jul 2007 → Jul 2010 | tick-borne encephalitis | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00163540 | May → Jun 2005 | tick-borne encephalitis | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00161967 | May 2005 → Jul 2008 | tick-borne encephalitis | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00161785 | Jun 2004 → Jul 2005 | tick-borne encephalitis | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00161954 | Mar → May 2004 | tick-borne encephalitis | Pfizer | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-02-23 | Pfizer | Regulatory U.S. FDA Accepts for Priority Review Pfizer’s Application for TicoVac™ (Tick-borne Encephalitis Vaccine) pfizer.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-02-23 | Pfizer | U.S. FDA Accepts for Priority Review Pfizer’s Application for TicoVac™ (Tick-borne Encephalitis Vaccine) pfizer.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FSME-Immun | “The objective of this study is to establish the earliest time point at which vaccines are expected to show seropositive antibody levels after vaccination with FSME-IMMUN 0.5 mL...” NCT00161954 ↗11“Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)” NCT00163540 ↗ “The studies presented here were conducted to obtain prospective long-term TBE serum antibody persistence data of subjects up to 10years after the first booster with FSME-IMMUN.” PMID 28545923 ↗ May 2017 “Subjects receive one vaccination with either FSME-IMMUN 0.25 ml or FSME-IMMUN 0.5 ml, depending on their age.” NCT00161967 ↗ “The objective of this study is to investigate the immunogenicity and safety of FSME-IMMUN 0.5 ml” NCT00460486 ↗ “Subjects receive three vaccinations with FSME-IMMUN 0.25ml Junior on days 0, 28 and 360” NCT00840801 ↗ “FSME-Immun, 0,5 ml, i.m., 1x Inflexal 0,5 ml, i.m., 1x” NCT00804219 ↗ |
| Known as | FSME-Immun 0.5 ml | “FSME-Immun 0.5 ml” NCT00890422 ↗ |
| Modality | Vaccine | “third TBE vaccination with FSME-IMMUN 0.5ml” NCT00161785 ↗ |
| Route | Intramuscular | “Vaccination by intramuscular injection into the right or left upper arm (musculus deltoideus)” NCT00503529 ↗ |